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No Evidence of Association Between
Anti–Tumor Necrosis Factor Treatment and Mortality in
Patients With Rheumatoid Arthritis
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Mark Lunt, Kath D. Watson, William G. Dixon, the British Society for Rheumatology
Biologics Register Control Centre Consortium, Deborah P. M. Symmons, and
Kimme L. Hyrich, on behalf of the British Society for Rheumatology Biologics Register
Objective. To study the association between anti–
tumor necrosis factor (anti-TNF) therapy and mortality
in a national cohort of patients with rheumatoid arthri-
tis.
Methods. We prospectively followed up 12,672
patients who were beginning anti-TNF therapy and
3,522 biologic-naive patients receiving disease-
modifying antirheumatic drugs (DMARDs) until either
July 31, 2008, or death, whichever occurred first. Noti-
fication of death and cause of death was received from
the UK National Death Register. Mortality was com-
pared using Cox proportional hazards models. Inverse
probability of treatment weighting was used to adjust
for the confounding effects of baseline differences be-
tween groups, including age, sex, disease severity, dis-
ability, and comorbidity. Missing baseline data were
accounted for using multiple imputation.
Results. When compared with the DMARD co-
hort, the anti-TNF cohort was younger (median age 57
years versus 61 years), had greater disease activity
(median Disease Activity Score in 28 joints 6.6 versus
5.1), and had greater disability (median Health Assess-
ment Questionnaire score 2.1 versus 1.6). Patients in the
DMARD cohort were more likely to have a history of
myocardial infarction (4.8% versus 3.1%) and chronic
obstructive pulmonary disease (8.1% versus 4.8%) but
were less likely to have had depression (16.5% versus
18.9%). There were 9,445 and 50,803 person-years of
followup in the DMARD and anti-TNF cohorts, respec-
tively, during which time 204 DMARD-treated and 856
anti-TNF–treated patients died. The weighted mortality
hazard ratios in the anti-TNF cohort were as follows:
all-cause 0.86 (95% confidence interval [95% CI] 0.64–
1.16), circulatory disease 0.73 (95% CI 0.44–1.23), neo-
plasm 0.65 (95% CI 0.39–1.09), and respiratory disease
0.81 (95% CI 0.36–1.83).
Conclusion. Our results indicate that, compared
with standard DMARD therapy, treatment with anti-
TNF therapies was not associated with an increase in
mortality.
Rheumatoid arthritis (RA) is a chronic systemic
inflammatory condition affecting the joints and other
connective tissues. In addition to chronic disability, RA
is associated with increased mortality (1). The leading
cause of excess mortality is cardiovascular disease, and
other common causes include infection, respiratory dis-
ease, and some malignancies. The reasons behind this
increased mortality are likely to be multifactorial and
may include the effects of chronic inflammation, disabil-
ity, and comorbidity. The effects of concurrent immu-
nosuppressive therapy also cannot be ruled out, al-
though the results of previous studies have suggested
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3145that the control of inflammation with methotrexate
(MTX) may improve mortality (2,3).
Recently a new therapeutic approach to RA has
been introduced. Unlike previous immunosuppressive
agents, which offered a blanket approach to immuno-
suppression, these new targeted therapies, including
anti–tumor necrosis factor (anti-TNF) agents, are di-
rected at single components of the immune response. In
the 10 years since their license, these drugs have been
shown to significantly improve the signs and symptoms
of RA and can improve disability (4–9). Whether or not
these treatments can also improve the mortality rates in
RA remains largely unknown. The findings of recent
studies have suggested that these drugs may be associ-
ated with an increased risk of serious infection, particu-
larly in the first few months of therapy (10), which may
therefore increase the risk of death when compared with
standard nonbiologic disease-modifying antirheumatic
drugs (DMARDs). However, data from observational
studies have also demonstrated that anti-TNF therapy
may decrease the risk of new cardiovascular events
(11,12), particularly among those patients who experi-
ence improvements in their disease activity, thus poten-
tially reducing overall mortality.
Few studies have investigated the risk of all-cause
mortality among patients receiving anti-TNF agents.
Both a Swedish study (13) and a Spanish study (14)
showed a significant reduction in mortality among pa-
tients treated with anti-TNF compared with patients
receiving nonbiologic DMARDs. However, one of the
challenges in assessing mortality risk within an observa-
tional study is taking into account those factors that may
be associated with both the prescription of the anti-TNF
therapy and the risk of death (confounding by indica-
tion). Patients who receive anti-TNF therapies often, by
definition, have the most severe disease, characterized
by high levels of disability, which is also a significant risk
factor for premature death (15). Conversely, patients
with high levels of baseline comorbidity (who are there-
fore at high risk of side effects) are preferentially not
prescribed anti-TNF therapy (confounding by contrain-
dication) but rather may remain on standard DMARD
therapies alone. This may result in anti-TNF death rates
significantly lower than those among non–anti-TNF–
treated patients. To explore this further, we compared
all-cause mortality between a cohort of patients starting
anti-TNF therapy and a cohort of patients with active
disease receiving standard DMARD therapy, using in-
verse probability of treatment weighting (IPTW) to
allow for differences in baseline risk of death.
PATIENTS AND METHODS
Patients. Patients included in this study were partici-
pants in the British Society for Rheumatology Biologics Reg-
ister (BSRBR) (16). Established in 2001, the BSRBR has been
actively recruiting patients with physician-diagnosed RA who
are starting 1 of the 3 available anti-TNF therapies: etanercept,
infliximab, or adalimumab. In the UK, the use of anti-TNF
agents is restricted to those patients with active disease,
defined as a patient with a Disease Activity Score in 28 joints
(DAS28) 5.1 (17), despite treatment with at least 2 standard
DMARDs, 1 of which should be MTX (18). The primary aim
of the BSRBR is to assess the long-term safety of these agents
in patients with RA, with a goal recruitment of at least 4,000
patients starting each of the 3 therapies. This target number of
patients was reached for etanercept in May 2005, for infliximab
in 2007, and for adalimumab at the end of 2008. Up until 2005,
when patients receiving all 3 anti-TNF therapies were being
actively recruited for the study, it was estimated that 7% of
all RA patients in the UK were receiving anti-TNF therapies
(19) and that the register was recruiting 80% of that total.
In addition to patients treated with anti-TNF thera-
pies, the BSRBR is recruiting and following a cohort of
biologic-naive patients with RA who have active disease
(DAS28 4.2) and who are receiving standard nonbiologic
DMARD therapy, again with a goal of 4,000 patients. Patients
in this cohort were recruited from 29 rheumatology centers
across the UK (see Appendix A). Recruitment of this cohort
was completed in March 2009, and subjects continued to be
followed up, even if they stopped or changed DMARD ther-
apy. The one exception was subjects in the comparison cohort
who subsequently started anti-TNF therapy. These patients
were followed up in the comparison cohort until the date they
were switched to a biologic agent and were followed up in the
biologic cohort from the date of the first dose of anti-TNF. If
a patient in the DMARD cohort was switched to a non–anti-
TNF biologic agent as their first biologic agent, they were
censored at the time of switch and were not followed up
further. Patients could not switch from the anti-TNF cohort to
the DMARD cohort.
Assessments. All patients, both anti-TNF and compar-
ison patients, were followed up in a similar manner. At the
start of anti-TNF therapy (or at the time of registration into
the DMARD cohort), a baseline questionnaire was completed
by the medical team that detailed diagnosis, disease activity,
past and current antirheumatic therapies, and other comor-
bidities. Comorbidities were selected from a list that included
hypertension, angina, myocardial infarction, stroke, epilepsy,
asthma, chronic obstructive pulmonary disease (COPD), pep-
tic ulcer disease, liver disease, renal disease, diabetes, depres-
sion, and previous neoplasm. The severity of each condition
was not specifically recorded. Only comorbidities recorded at
baseline were included in the analysis. Patients also completed
a Health Assessment Questionnaire (HAQ) adapted for Brit-
ish use (20).
Followup took place at 6-month intervals for the first 3
years and annually thereafter. At each followup visit, the
hospital staff completed a questionnaire detailing any changes
to antirheumatic therapy, current disease activity, and any new
adverse events, including death. For the first 3 years of the
study, the patient also completed a diary every 6 months,
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Finally, all patients were flagged by the National Health
Service (NHS) Central Register, part of the NHS Information
Centre for Health and Social Care (NHS-IC) (online at
http://www.ic.nhs.uk/). In the UK, there is a statutory require-
ment to report all births, deaths, and cancers to the Central
Register. In cases of death, this must also include the under-
lying and contributing causes of death. These are all coded
centrally according to the International Statistical Classifica-
tion of Diseases and Related Health Problems, Tenth Revision
(ICD-10). The Central Register database collects from multi-
ple possible sources. In the event of a death, the coroner,
hospital, or general practitioner submits information, including
cause of death, to the local health authority, which electroni-
cally passes this information on to the Central Register on a
weekly basis. Researchers can “flag” their subjects with the
NHS-IC, which will then provide, on a quarterly basis, the
details of all deaths, including a copy of the death certificate.
Even if a patient is lost to followup, the details of that patient’s
death will be provided to researchers by the NHS-IC.
The study received ethical approval from the North
West Multi-Centre Research Ethics Committee (MREC 00/8/
53), and all patients provided written informed consent.
Statistical analysis. The primary outcome measure in
this study was death. Mortality rates among the anti-TNF–
treated and the comparison cohorts were compared using Cox
proportional hazards models and are presented as hazard
ratios (HRs) and 95% confidence intervals (95% CIs). Patients
were followed up from the date they first received an anti-TNF
drug (or the date of registration for the comparison cohort)
until either July 31, 2008, or death, whichever came first.
Patients receiving anti-TNF therapy were followed up even if
they discontinued the drug or switched to an alternative
biologic agent. All-cause mortality and cause-specific mortality
were analyzed for neoplasm (ICD-10, Chapter II), circulatory
disease (ICD-10, Chapter IX), and respiratory disease (ICD-
10, Chapter X). In all cases, the underlying cause of death,
obtained from the death certificate, was used in the analysis.
All analysis was performed using Stata 10.1 (StataCorp).
Adjusting for baseline differences between treated and
untreated patients. Since this was an observational study, pa-
tients were not randomized to their treatment groups, and so,
the anti-TNF–treated group and the comparison group may
differ in variables that influence mortality, such as disease
severity and comorbidity. Hence, a direct comparison of
mortality rates will not reflect the effect of anti-TNF treat-
ment. To allow for baseline differences in covariates, IPTW
was used (21). Briefly, this method uses logistic regression to
calculate, for each individual, the probability (P[x]) (also
known as the propensity score) that they would be in the
anti-TNF cohort given their baseline variables x. By giving a
weight of 1/P(x) to all subjects in the anti-TNF cohort, and
1/(1–P[x]) to subjects in the comparison cohort, the distribu-
tion of the baseline variables in each cohort is made equal to
the distribution in both cohorts combined.
To assess the need for balancing, and the extent to
which it was achieved by weighting, we used a method that we
have described previously (22). The degree to which an
individual variable confounds the association between out-
come and exposure can be assessed by measuring the unad-
justed effect of treatment, then repeating the analysis, adjust-
ing for the variable of interest to the extent possible. If the
estimate of the treatment effect changes, this change implies
that the covariate was a confounder. The change in the
treatment effect estimate, after confounding has been removed
by reweighting, gives a measure of how successful the reweight-
ing has been. When adjusting for potential confounders,
continuous variables were fitted after categorizing into quin-
tiles, to avoid assuming a linear association between covariate
and outcome.
Trimming. One potential problem with IPTW is that
unusual subjects can be given very high weights, i.e., subjects
who were very good candidates for treatment but did not
receive it will have a low probability of not receiving treatment,
and hence, a high weight in the analysis. This can lead to bias,
if there was a reason that these subjects did not receive
treatment that was not captured in the propensity score
(unmeasured confounding). We therefore compared the
IPTW estimate with the estimates generated by setting all
weights 20 to be equal to 20, as recommended by Cole and
Hernan (23), and by excluding all subjects with weights 20.
Multiple imputation. One problem with adjusting for a
large number of variables is that it increases the probability
that a given subject will have missing data on at least one
variable, and hence, will be excluded from a naive analysis,
which may introduce bias. To avoid this bias, multiple impu-
tation was used, with 20 data sets being imputed using chained
regression, utilizing the Ice package in Stata (24,25). The effect
of the imputation was assessed by looking at the fraction of
missing information, which measures how the uncertainty
about an estimate has been increased by the missing data.
Technically, it is given as
1–VIMP/VFULL
where VIMP is the variance of the estimate in the multiply
imputed data and VFULL is the expected value of the variance
of the estimate if there had been no missing data.
RESULTS
Through July 31, 2008, 12,672 patients with RA
were recruited for the cohort receiving anti-TNF treat-
ment (4,420 patients receiving etanercept, 4,161 patients
receiving infliximab, and 4,091 patients receiving adali-
mumab). The median age was 57 years, and 76% were
women (Table 1). Patients had a high level of baseline
disease activity (median DAS28 6.6), as well as high
baseline levels of disability (median HAQ score 2.1).
More than 50% of patients had a comorbid condition at
baseline, with the most common conditions being hyper-
tension, depression, asthma/COPD, and peptic ulcer
disease.
When compared with the anti-TNF cohort, the
nonbiologic DMARD cohort (n  3,522) was slightly
older and had a higher proportion of men. Although
these patients had slightly lower levels of disease activity
than patients receiving anti-TNF therapy, their disease
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they had moderate levels of disability (median HAQ
score 1.6). A similar proportion of patients as that
observed in the anti-TNF cohort had a comorbid condi-
tion, although angina, asthma, COPD, and/or previous
neoplasm were more common in the nonbiologic
DMARD group (Table 1). In the nonbiologic DMARD
cohort, 173 patients subsequently started anti-TNF ther-
apy during followup and were followed up for a time in
both cohorts.
As of July 31, 2008, there were a total of 50,803
person-years in the anti-TNF cohort (mean followup 4
years) and 9,445 person years in the nonbiologic
DMARD cohort (mean followup 2.7 years). During this
time, there were 856 deaths in the anti-TNF cohort and
204 deaths in the comparison cohort. Data on the
underlying causes of death, classified according to the
ICD-10, were available for 98.4% of the cohort and are
listed in Table 2. The leading causes of death were
circulatory disease, neoplasm, respiratory disease, and
Table 1. Distribution of covariates and the impact of adjustment on the estimated relative rate of mortality in patients receiving
anti-TNF therapy versus patients receiving nonbiologic DMARD therapy*
Anti-TNF–
treated patients
(n  12,672)
Nonbiologic
DMARD–
treated patients
(n  3,522)
Change in rate ratio, %†
Unweighted Weighted
Age, median (IQR) years 57 (48–65) 61 (52–69) 40 3
Disease duration, median (IQR) years 11 (6–19) 6 (1–15) 6 1
Disease Activity Score, median (IQR) 6.6 (5.9–7.3) 5.1 (4.3–6.0) 18 2
Health Assessment Questionnaire, median (IQR) score 2.1 (1.8–2.5) 1.6 (0.9–2.1) 18 5
Blood pressure, median (IQR) mm Hg
Systolic 134 (120–149) 136 (122–150) 3 5
Diastolic 80 (71–87) 80 (72–87) 2 5
Sex, female 76.2 72.3 2 1
Number of DMARDs taken previously
1 1.8 29.7 15 1
2 18.5 28.5
3 26.1 20.5
4 20.7 11.6
5 15 5.4
6 17.9 4.3
BMI, kg/m
2
20 8.7 6.3 0 2
20–25 34.1 32.8
25–30 32.6 35.2
30 24.6 25.7
Smoking status
Never 40.3 36.6 3 1
Former 37.8 39.7
Current 21.9 23.7
History of other conditions
Hypertension 29.7 31.8 1 2
Angina 4.5 7.8 5 2
Myocardial infarction 3.1 4.8 3 0
Stroke 2.1 3.2 1 0
Epilepsy 1.1 1.1 0 0
Asthma 9.9 13.5 1 1
COPD 4.8 8.1 5 1
Peptic ulcer disease 8.5 7.3 10
Liver disease 2 2 0 1
Renal disease 2.5 2.9 0 1
Diabetes 5.7 6.7 1 0
Depression 18.9 16.5 0 1
Neoplasm 3.2 6.8 2 1
* Except where indicated otherwise, values are the percent of patients. Anti-TNF  anti–tumor necrosis factor; DMARD 
disease-modifying antirheumatic drug; IQR  interquartile range; BMI  body mass index; COPD  chronic obstructive pulmonary
disease.
† Calculated according to the formula RRA –R R C/RRC, where RRC is the crude rate ratio and RRA is the rate ratio after adjustment
for the variable in question. This allows measurement of the extent to which the variable is confounding the rate ratio.
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tionately more people in the DMARD comparison
group than in the anti-TNF group died of a neoplasm
(32% versus 20%). There was a higher proportion of
deaths in the anti-TNF group than in the comparison
group resulting from diseases of the musculoskeletal
system (15% versus 5%), primarily RA. Of note, RA was
listed on the death certificate of only 31% of patients.
Other causes of death were equally distributed between
the 2 groups.
All-cause mortality rates are presented in Table
3. Within the nonbiologic DMARD cohort, the unad-
justed mortality rates differed based on whether or not
complete baseline data on covariates were present, with
a higher mortality rate among those patients with miss-
ing data. This effect was not observed in the anti-TNF
cohort. After imputing data on missing covariates and
adjusting for baseline differences, we found no overall
difference in mortality rates between the anti-TNF
cohort and the nonbiologic DMARD cohort (weighted
HR 0.86 [95% CI 0.64–1.16]) (Figure 1). A similar
pattern of mortality risk was found for each of the 3
leading causes of death within the cohort as follows: for
circulatory disease, weighted HR 0.73 (95% CI 0.44–
1.23), for neoplasm, weighted HR 0.65 (95% CI 0.39–
1.09), and for respiratory disease, weighted HR 0.81
Table 2. Underlying causes of death, as recorded on the death certificate, among patients in the anti-TNF and nonbiologic DMARD cohorts,
classified according to ICD-10 chapter number*
Chapter Blocks Chapter title
Deaths in the
anti-TNF cohort
(n  856)
Deaths in the
nonbiologic
DMARD cohort
(n  204)
I A00–B99 Certain infectious and parasitic diseases 35 (4) 5 (2)
II C00–D48 Neoplasm 167 (20) 65 (32)
III D50–D89 Diseases of the blood and blood-forming organs and certain
disorders involving the immune mechanism
5 (0.6) 1 (0.5)
IV E00–E90 Endocrine, nutritional and metabolic diseases 10 (1) 1 (0.5)
VI G00–G99 Diseases of the nervous system 8 (1) 1 (0.5)
IX I00–I99 Diseases of the circulatory system 255 (30) 67 (33)
X J00–J99 Diseases of the respiratory system 132 (15) 33 (16)
XI K00–K93 Diseases of the digestive system 54 (6) 2 (1)
XII L00–L99 Diseases of the skin and subcutaneous tissue 8 (1) 1 (0.5)
XIII M00–M99 Diseases of the musculoskeletal system and connective tissue 131 (15) 10 (5)
XIV N00–N99 Diseases of the genitourinary system 21 (2) 6 (3)
XX V01–Y98 External causes of morbidity and mortality 16 (2) 3 (1)
Other chapters – – 5 (0.6) 1 (0.5)
Not coded – – 9 (1) 8 (4)
* Values are the number (%) of patients. Only those chapters of the International Statistical Classification of Diseases and Related Health Problems,
Tenth Revision (ICD-10) that were used to classify 5 deaths are shown. Other causes of death included mental and behavioral disorders (2 patients
in the anti-TNF cohort), disease of the ear and mastoid process (1 patient in the anti-TNF cohort), congenital malformations (1 patient in the
anti-TNF cohort), injury or poisoning (1 patient in the nonbiologic DMARD cohort), and symptoms, signs, and abnormal clinical and laboratory
findings (1 patient in the anti-TNF cohort). See Table 1 for other definitions.
Table 3. All-cause mortality rates in the anti-TNF and nonbiologic DMARD cohorts*
Anti-TNF cohort Nonbiologic DMARD cohort
HR
No. of
patients
Person-
years
Mortality rate
per 1,000
person-years
(95% CI)
No. of
patients
Person-
years
Mortality rate
per 1,000
person-years
(95% CI)
Patients with complete baseline data,
unadjusted analysis
9,788 38,488 16.6 (15.4–17.9) 2,518 6,767 19.1 (16.1–22.6) 0.83 (0.68–1.00)
Patients with incomplete baseline
data, unadjusted analysis
2,884 12,315 17.6 (15.4–20.1) 1,004 2,678 28.0 (22.3–35.1) 0.60 (0.46–0.79)
All patients, unadjusted analysis 12,672 50,803 16.8 (15.8–18.0) 3,522 9,445 21.6 (18.8–24.8) 0.74 (0.63–0.86)
All patients, weighted analysis 12,672 50,026 16.3 (14.9–17.8) 3,522 9,836 17.9 (13.5–23.6) 0.86 (0.64–1.16)
* 95% CI  95% confidence interval; HR  hazard ratio (see Table 1 for other definitions).
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influence of treatment changed with the propensity
score (P  0.6) or that the assumption of proportional
hazards was violated (P  0.5). Truncating the IPTW at
20 did not affect the estimate of the HRs, nor did any of
the following: excluding patients with weights 20,
excluding untreated subjects with propensity scores
lower than any treated subject, and excluding treated
subjects with propensity scores higher than any un-
treated subject.
DISCUSSION
The results of this large national prospective
cohort study have demonstrated that, when compared
with standard nonbiologic DMARD therapy, anti-TNF
therapy is not associated with either a significant in-
crease or decrease in mortality. Furthermore, the indi-
vidual causes of death did not differ substantially be-
tween these two groups, suggesting that, in the short
term (mean 4 years), anti-TNF therapy does not seem to
convey any additional risk or benefit on overall mortality
risk when compared with standard nonbiologic
DMARD therapy.
The findings in this study are in contrast to the
findings of 2 previous studies on mortality and anti-TNF
therapy: one from the Base de Datos de Productos
Biolo ´gicos de la Sociedad Espan ˜ola de Reumatologı ´a in
Spain and the other from the South Swedish Arthritis
Treatment Group, both of which showed a substantial
reduction in mortality among patients receiving anti-
TNF therapy compared with that among patients receiv-
ing standard DMARD therapy (13,14). Unfortunately,
the relatively small size of these studies (20 deaths in the
Spanish study and 51 deaths in the Swedish study)
prevented a detailed breakdown of the underlying
causes of death. Furthermore, due to differences in
study design, there was a limitation as to which con-
founders could be considered in the analyses.
The Spanish study was only able to adjust the full
analysis by age and sex, after which a mortality ratio of
0.32 (95% CI 0.20–0.53) in anti-TNF–treated patients
versus control patients was found. It is interesting to
note that, in the Spanish study, the standardized mor-
tality ratio in anti-TNF–treated patients, primarily re-
cruited prior to 2002, was only 0.5. This is significantly
lower than that which might be expected among a group
of patients with severe RA requiring anti-TNF therapy,
suggesting that a degree of channeling bias was present.
The Swedish study included adjustment for a wide
variety of disease-related features, including disease
activity and disability, although adjustment for comor-
bidity was limited to COPD, diabetes, and cardiovascu-
lar disease. The authors of that study still found a
reduction in overall mortality in anti-TNF–treated pa-
tients (HR 0.65 [95% CI 0.46–0.93]), although this
reduction was only statistically significant among female
patients in a further analysis stratified by sex.
One of the biggest challenges of these types of
analyses is balancing the differences between patients
receivinganti-TNFtherapyandpatientsreceivingnonbio-
logic DMARD therapy. By definition, patients with the
most severe disease will go on to receive anti-TNF
therapy. Similarly, patients who have a contraindication
to anti-TNF therapy but have ongoing high disease
Figure 1. Kaplan-Meier survival curves showing all-cause mortality, both before adjustment (left) and after adjustment (right)
for baseline differences, among patients receiving anti–tumor necrosis factor therapy (exposed) versus patients receiving
nonbiologic DMARD therapy (unexposed).
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sion to treat or not to treat is not random but is based
highly on a number of patient-related factors, many of
which also influence the risk of death. This may explain
why we observed a higher proportion of deaths from
severe RA in the anti-TNF–treated group but a higher
proportion of deaths from neoplasm, a relative contra-
indication for treatment (18), in the control group.
Indeed, when confounding factors were not taken into
consideration, the unadjusted mortality estimate in the
current analysis also suggested lower death rates in the
anti-TNF group (HR 0.74 [95% CI 0.63–0.86]), similar
to the findings of previous studies (13,14).
In this study, we also observed a small proportion
of patients who were originally enrolled in the DMARD
cohort and then consented to further enrollment in the
anti-TNF cohort when starting anti-TNF therapy. It is
possible that these patients may have been healthier
than those who remained in the DMARD cohort or
those who were originally registered in the anti-TNF
cohort, and thus, may have reduced the observed mor-
tality risk as well, although the size of this cohort makes
a significant effect on our results unlikely.
One option for balancing observed differences
between treated and untreated subjects is to employ a
propensity score. There are a number of ways of using
the propensity score to adjust for baseline differences
between treatment groups, which can be thought of as
assessing the mean effect of treatment in different
populations (22). The IPTW method used in the current
study compares the expected outcome if all subjects
were to switch to anti-TNF therapy with the expected
outcome if all subjects were to continue on DMARDs. It
is important to note that the comparison presented is
between a plan to switch to anti-TNF treatment and a
plan to continue with nonbiologic DMARD treatment,
with the decision being made when the subject enters the
study. Therefore, both arms of the analysis (both the
anti-TNF cohort and the DMARD cohort) should
ideally be as similar as possible at that specific point in
time.
The strength of this study is its size and the vast
collection of potential confounding information at base-
line, as well as the prospective collection of followup
data. We also had the benefit of a true internal compar-
ison cohort of patients for whom the same detailed
baseline information was collected. Because of the work
of the NHS-IC, we were also assured of almost 100%
followup of a patient’s vital status. The cause of death
was known in all but 17 patients. In a number of these
missing cases, death occurred outside the UK, and no
death certificate was available, although the death and
date of death were confirmed by a rheumatologist, thus
allowing inclusion in our all-cause mortality analysis.
A potential limitation of the current study was
the effect of missing data at baseline. Although every
effort was made to collect comprehensive data on all
patients, in many cases, certain elements of the baseline
covariates were missing. It was interesting to observe
that the mortality rate was markedly higher among
comparison subjects with incomplete data (28 per 1,000
person-years) than among comparison subjects with
complete data (19 per 1,000 person-years). The unad-
justed HR was 0.83 among subjects with complete data,
compared with 0.74 in all subjects, an overestimate of
12%. The reasons for this discrepancy are not entirely
clear. The most frequent missing data item in the
nonbiologic DMARD group was the HAQ score. It may
be that patients with multiple comorbidities or an ele-
ment of frailty were not able to complete these forms,
thus introducing the potential for bias into our data.
However, although there were missing data items, we
were not missing the patient information required to
impute missing data. Indeed, 2% of information was
missing with regard to calculation of HRs in the
weighted analysis. This justifies the use of multiple
imputation to obtain an unbiased estimate in our analy-
sis.
One risk of studying all-cause mortality is that
there may be individual trends within specific causes of
death that may be overlooked. The 3 leading causes of
death in the current study were circulatory disease,
neoplasm, and respiratory disease. We have previously
shown that the overall risk of early myocardial infarction
was similar between our anti-TNF and nonbiologic
DMARD groups, although patients whose RA had
responded to the initial anti-TNF agent at 6 months had
lower rates of myocardial infarction (11). In the current
study, although we saw a trend toward a reduction in
death from circulatory disease, this did not reach statis-
tical significance. Similarly, we saw a reduced point risk
estimate for death due to neoplasm in the anti-TNF
cohort, although again this did not reach statistical
significance. It is possible that, with longer followup, a
different pattern of risk from that observed in this study
may emerge. In addition, since many of these diagnoses
will not be fatal over a short period, the data cannot be
used to extrapolate information on the differences in
overall incidence of cardiac disease and neoplasm in the
2 cohorts.
A remaining challenge in the analysis of observa-
tional data is an understanding of the role that baseline
ANTI-TNF THERAPY AND MORTALITY IN PATIENTS WITH RA 3151comorbidities have in the risk of cause-specific death. In
the current study, we were able to adjust for a number of
comorbidities present at baseline; however, we were not
able to adjust for the severity of these comorbidities. It
is possible that there remains a channeling bias of
healthier patients toward anti-TNF therapies, which, in
part, may explain the trends observed in some of our
results. However, a suggestion that disease control can
also have beneficial effects on long-term outcomes sug-
gests that this is not the only explanation for these
trends.
We did not include a specific analysis of infection
as an underlying cause of death. First, infection is not a
single category within the ICD but instead crosses many
ICD chapters. In addition, this analysis included the
underlying cause of death and not the immediate cause
of death, which is where infection may be more likely to
be categorized (e.g., death from pneumonia following
cerebrovascular accident). However, previous studies
have shown that serious infections (those resulting in
hospitalization and/or death) are increased in patients
receiving anti-TNF therapy, particularly in the early
months of treatment. Whether this is related to a total
increase in death from infection over time is less clear.
In conclusion, this analysis of all-cause and cause-
specific mortality in a large UK cohort of patients with
severe RA has demonstrated that treatment with anti-
TNF therapies over a mean of 4 years is not associated
with an increased risk of death, as compared with
treatment with standard DMARD therapy alone. Future
analysis will confirm if this trend in mortality, including
the underlying causes of death observed in both cohorts,
is maintained over longer periods of followup.
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APPENDIX A: BSRBR CONTROL CENTRE
CONSORTIUM
The BSRBR Control Centre Consortium consists of the
following institutions (all in the UK): Antrim Area Hospital, Antrim
(Dr. Nicola Maiden), Cannock Chase Hospital, Cannock Chase (Dr.
Tom Price), Christchurch Hospital, Christchurch (Dr. Neil Hopkin-
son), Derbyshire Royal Infirmary, Derby (Dr. Sheila O’Reilly), Dews-
bury and District Hospital, Dewsbury (Dr. Lesley Hordon), Freeman
Hospital, Newcastle-upon-Tyne (Dr. Ian Griffiths), Gartnavel General
Hospital, Glasgow (Dr. Duncan Porter), Glasgow Royal Infirmary,
Glasgow (Professor Hilary Capell), Haywood Hospital, Stoke-on-
Trent (Dr. Andy Hassell), Hope Hospital, Salford (Dr. Romela
Benitha), King’s College Hospital, London (Dr. Ernest Choy), Kings
Mill Centre, Sutton-In-Ashfield (Dr. David Walsh), Leeds General
Infirmary, Leeds (Professor Paul Emery), Macclesfield District Gen-
eral Hospital, Macclesfield (Dr. Susan Knight), Manchester Royal
Infirmary, Manchester (Dr. Ian Bruce), Musgrave Park Hospital,
Belfast (Dr. Allister Taggart), Norfolk and Norwich University Hos-
pital, Norwich (Professor David Scott), Poole General Hospital, Poole
(Dr. Paul Thompson), Queen Alexandra Hospital, Portsmouth (Dr.
Fiona McCrae), Royal Glamorgan Hospital, Glamorgan (Dr. Rhian
Goodfellow), Russells Hall Hospital, Dudley (Professor George Ki-
tas), Selly Oak Hospital, Selly Oak (Dr Ronald Jubb), St. Helens
Hospital, St. Helens (Dr. Rikki Abernethy), Weston General Hospital,
Weston-super-Mare (Dr. Shane Clarke/Dr. Sandra Green), Withing-
ton Hospital, Manchester (Dr. Paul Sanders), Withybush General
Hospital, Haverfordwest (Dr. Amanda Coulson), North Manchester
General Hospital, Manchester (Dr. Bev Harrison), Royal Lancaster
Infirmary, Lancaster (Dr. Marwan Bukhari), and The Royal Oldham
Hospital, Oldham (Dr. Peter Klimiuk).
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